Summary

Overview
The global achalasia treatment market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Achalasia is an uncommon disorder that makes it difficult for food and drink to flow from mouth to stomach via the swallowing tube (esophagus). When the nerves in the esophagus are injured, achalasia develops.
Achalasia has been classified as a rare disorder, with an annual incidence of 6 cases per 100,000 individuals and a prevalence of ten instances per 100,000 people. Despite the shortage of medical knowledge on achalasia, its prevalence seems to be increasing. In individuals with triple-A syndrome or Allgrove syndrome, a rare autosomal recessive genetic condition, achalasia is also related to adrenal insufficiency and alacrima.
Achalasia is defined by increasing upset of solids and liquids. Patients with achalasia square measure misdiagnosed with esophageal reflux sickness (GERD) and treated with nucleon pump matter (PPI) medical aid as a result of their need for pyrosis. Misdiagnosis of GERD typically results in a big delay in diagnosis of achalasia till patients have continuous symptoms that eventually cause the right identification. Patients of all ages have upset and regurgitation, however younger patients square measure additional likely to expertise pain and pyrosis. fat patients (BMI 30) could expertise additional frequent choking or vomiting symptoms.
Market Dynamics: Drivers
Increasing Prevalence and Awareness & Availability of Achalasia Treatments
The demand for the achalasia treatment market is driven by multiple factors. Achalasia is a rare esophageal disorder characterized by symptoms of progressive dysphagia and regurgitation. According to gastroenterology & endoscopy news in May 2024, the incidence is estimated to be between 0.8 and 2.2 cases per 100,000 individuals, with a prevalence of 7.0 to 15.3 cases per 100,000 persons.
Despite the lack of epidemiologic data on achalasia, its prevalence appears to be increasing. In people with triple-A syndrome or Allgrove syndrome, a rare autosomal recessive genetic condition, achalasia may be associated with adrenal insufficiency and alacrima.
Achalasia is characterized by increasing dysphagia of solids and liquids. Patients with achalasia are frequently misdiagnosed with gastroesophageal reflux disease (GERD) and treated with proton pump inhibitor (PPI) therapy because they have heartburn.
Misdiagnosis of GERD often leads to a significant delay in diagnosing achalasia until patients have continuous symptoms that eventually lead to the correct diagnosis. Patients of all ages have dysphagia and regurgitation, but younger patients are more likely to experience chest pain and heartburn. Obese patients (BMI 30) may experience more frequent choking or vomiting symptoms.
The specific cause of achalasia remains unknown. It could be caused by a loss of nerve cells in the esophagus, according to researchers. There are a few theories about why this happens, but viral infection or autoimmune reactions have been suggested. Hence, the increasing prevalence of achalasia and its related symptoms is estimated to drive the market.
Moreover, key players in the industry's financial investment and well-defined healthcare infrastructure would drive the market. For instance, in March 2024, the financial implications of achalasia are significant, with an estimated $400 million spent annually on its management in the United States alone. Given the personal and financial burdens of achalasia, it is crucial to understand strategies for its effective management.
Moreover, key players introduce innovative procedures to propel this market. As per Times of India news in July 2022, POEM is an endoscopic procedure used to treat obstruction at the lower end of the food pipe due to failure of relaxation of the lower esophageal sphincter (musculature opening) due to a motility disorder called achalasia cardia. A 6-year-old underweight girl undergoes an endoscopic procedure for obstruction in a food pipe in Delhi.
Restraints
Factors such as the misdiagnosis of achalasia, adverse effects & risks associated with the treatment, lack of awareness & diagnosis, and high cost of the treatment are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The achalasia treatment market is segmented based on drug type, route of administration, distribution channel and region.
The calcium channel blockers segment accounted for approximately 43.2% of the achalasia treatment market share
The calcium channel blockers segment is expected to hold the largest market share over the forecast period. Calcium channel blockers have previously been found to lower esophageal sphincter (LES) pressure and relieve achalasia symptoms. Calcium channel blockers, such as Nifedipine, are increasingly routinely prescribed and administered sublingually 15-30 minutes before meals.
These inhibit the contractility of muscle cells by limiting calcium uptake intracellularly. There have been reports of success rates as high as 65-80%. Calcium channel blockers prevent calcium from being taken up by cells, preventing contraction and increasing relaxation. Nifedipine has been demonstrated to lower LES pressures and give symptomatic relief, while its efficacy is variable, with benefits reported in 50% to 90% of patients.
Calcium channel blockers may be the first line of treatment for high or moderate-risk achalasia patients before pneumatic dilatation or surgical myotomy. These drugs relax the muscles of the lower esophageal sphincter, allowing food and drink to move more freely into the stomach in persons with achalasia. Nitrates and calcium channel blockers are taken by mouth 10 to 30 minutes before a meal. They come in tablet form that can be taken under the tongue.
Moreover, key player strategies such as partnerships &collaborations would drive this market. For instance, in 2023, the acquisition of certain assets of action-prescribed drugs INC. by Bausch Health Firms INC. TRULANCE (plecanatide), Synergy's flagship product, could be a once-daily pill approved for adults with chronic upset constipation (CIC) and irritable gut syndrome with constipation (IBS-C), and dolcanatide, the company's investigational compound, is an incremental peptide with established proof-of-concept studies in multiple GI conditions are going to be extra to their product portfolio with this acquisition.
Geographical Analysis
North America accounted for approximately 41.7% of the achalasia treatment market share
North America region is expected to hold the largest market share over the forecast period. Achalasia affects about 2,000 people in the United States every year. According to studies carried out, 30000 patients were hospitalized over eight years for the treatment of esophageal achalasia in the United States.
This region has developed many new minimally invasive surgeries. For example, The GI surgery team at UC Davis excels in using a robotic-assisted, laparoscopic esophageal Heller myotomy to treat achalasia patients. Miniaturized devices and small incisions are used in the treatment, making it minimally invasive and contributing to faster recovery times and better outcomes. UC Davis Medical Center's GI surgery team consists of highly skilled and experienced surgeons, nurses, and technicians. A team of surgeons has extensively trained the da Vinci robotic surgical system.
More recently, UCLA and a few other institutes have begun doing per-oral endoscopic myotomy, or POEM. This procedure tries to replicate the Heller myotomy in a less intrusive manner. Advances in endoscopic procedures, such as submucosal endoscopy and natural orifice transluminal endoscopic surgery, or NOTES, made POEM conceivable. Hence, the use of advanced technology and the rising incidence of achalasia in this region is assumed to dominate the market.
Moreover, key players in this region introduce innovative procedures to propel this market. For instance, in April 2023, a Johns Hopkins Gastroenterologist first in the U.S. to perform POEM+F?a recently developed approach for Achalasia and acid efflux.
More than a decade ago, Khashab pioneered peroral endoscopic myotomy, alternatively known as POEM, in the United States ? an operation that loosens achalasia’s characteristic tightening of the lower esophageal sphincter.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the achalasia treatment market. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. All the other treatments and drug approvals were delayed due to the demand for COVID-19 treatment. This has affected the global achalasia treatment market as many have stopped manufacturing units.
Market Segmentation
By Drug Type
- Calcium Channel Blockers (CCBs)
- Nitrates
- Botulinum toxin Injection
- Others
By Route of Administration
- Injectable
- Oral
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the achalasia treatment market include Bausch Health US LLC., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Pfizer Inc., Accordhealthcare, AdvaCare Pharma, Merz Therapeutics, Sun Pharma Industries Ltd, Accordhealthcare, Galderma and Aetna among others.
Key Developments
- On April 25, 2024, Alberta introduces a minimally invasive procedure for a swallowing disorder. Albertans patients who need treatment for severe eating difficulty can obtain it in the province of Alberta. GI surgeons and thoracic surgeons at Edmonton's Royal Alexandra Hospital and Calgary's Foothills Medical Centre are now providing a procedure that is barely invasive to treat achalasia, a disorder of the nervous system that leads to excessive rigidity of the skeletal muscle connecting the esophagus and stomach.
- On April 23, 2024, Northside Hospital Gwinnett expanded its Interventional Gastrointestinal (GI) Endoscopy Program with a series of new, minimally invasive procedures that are available in Gwinnett County and surrounding communities.
- On February 17, 2023, Galway University Hospitals (GUH) became the first hospital in Ireland to implement an 'incision-less' minimally invasive procedure to assist treat esophageal obstructions. Traditionally, treatment of Achalasia involves procedures to repeatedly dilate/open the esophagus or require laparoscopic surgery. The traditional surgery divides the muscles of the lower esophagus through several small incisions in the abdomen.
Why Purchase the Report?
- To visualize the achalasia treatment market segmentation based on drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of achalasia treatment market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The achalasia treatment market report would provide approximately 62 tables, 51 figures, and 182 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence and Awareness & Availability of Achalasia Treatments
4.1.2. Restraints
4.1.2.1. The Misdiagnosis of Achalasia
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Calcium Channel Blockers (CCB’s)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Nitrates
7.4. Botulin Toxin Injections
7.5. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Injectable *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Retail Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospital Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Bausch Health US LLC *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Teva Pharmaceutical Industries Ltd.
12.3. Zydus Pharmaceuticals (USA) Inc
12.4. Pfizer Inc.
12.5. Accordhealthcare
12.6. AdvaCare Pharma
12.7. Merz Therapeutics
12.8. Galderma
12.9. Sun Pharma Industries Ltd
12.10. Aetna Inc
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us